152 related articles for article (PubMed ID: 2751287)
1. In vitro activities of amifloxacin and two of its metabolites.
Venezia RA; Prymas LA; Shayegani A; Yocum DM
Antimicrob Agents Chemother; 1989 May; 33(5):762-6. PubMed ID: 2751287
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
Neu HC; Labthavikul P
Diagn Microbiol Infect Dis; 1985 Nov; 3(6):469-78. PubMed ID: 4064609
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of amifloxacin (WIN 49,375) compared with those of ciprofloxacin and ofloxacin.
Digranes A
Acta Pathol Microbiol Immunol Scand B; 1987 Feb; 95(1):29-32. PubMed ID: 3105246
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of T-3761, a new fluoroquinolone.
Muratani T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
[TBL] [Abstract][Full Text] [Related]
6. Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria.
John JF; Twitty JA
Antimicrob Agents Chemother; 1984 Nov; 26(5):781-4. PubMed ID: 6440481
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome.
Appelbaum PC; Spangler SK; Sollenberger L
J Antimicrob Chemother; 1986 Dec; 18(6):675-9. PubMed ID: 3469178
[TBL] [Abstract][Full Text] [Related]
8. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
Ismaeel NA; Tayeb OS
Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.
Smith BR; LeFrock JL; Donato JB; Joseph WS; Weber SJ
Antimicrob Agents Chemother; 1986 Feb; 29(2):355-8. PubMed ID: 3717937
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin).
Cornett JB; Wagner RB; Dobson RA; Wentland MP; Bailey DM
Antimicrob Agents Chemother; 1985 Jan; 27(1):4-10. PubMed ID: 3885845
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
[TBL] [Abstract][Full Text] [Related]
12. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
McCarter YS; Mazens-Sullivan MF; Bartlett RC
Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
Rolston KV; LeBlanc B; Ho DH; Bodey GP
J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
[TBL] [Abstract][Full Text] [Related]
15. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
Bassey CM; Baltch AL; Smith RP
J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the new fluoroquinolone CP-99,219.
Neu HC; Chin NX
Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
Rolston KV; Nguyen H; Messer M; LeBlanc B; Ho DH; Bodey GP
Antimicrob Agents Chemother; 1990 Nov; 34(11):2263-6. PubMed ID: 2127348
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.
Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Domagala JM; Heifetz CL
Antimicrob Agents Chemother; 1991 Jan; 35(1):141-6. PubMed ID: 2014970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
